Table 2 Clinical characteristics of AML patients according to the richness of their pretreatment bone marrow T cell repertoire after the first course of azacitidine (day 15).
AML patients with top 25% richest repertoires (n = 12) | other AML patients (n = 34) | Pa | |
|---|---|---|---|
age at diagnosis median (range) | 65.6 (60.8–80.9) | 70.5 (60.9–83.5) | 0.23 |
AML origin, n (%) | |||
de novo | 8 (66.7) | 17 (50.0) | 0.50 |
secondary | 4 (33.3) | 17 (50.0) | |
BM blasts at day 0, % median (range) | 33 (0–80) | 47.5 (0–90) | 0.48 |
BM blasts at day 15, % median (range) | 27.5 (8–72) | 33 (5.4–80) | 0.37 |
NPM1 mutation | |||
present | 3 (25.0) | 7 (20.6) | 0.70 |
absent | 9 (75.0) | 27 (79.4) | |
FLT3-ITD mutation | |||
present | 3 (25.0) | 4 (11.8) | 0.36 |
absent | 9 (75.0) | 30 (88.2) | |
normal karyotype | |||
present | 5 (41.7) | 16 (47.1) | 0.39 |
absent | 6 (50.0) | 18 (52.9) | |
unknown | 1 (8.3) | 0 (0.0) | |
complex karyotype | |||
present | 3 (25.0) | 3 (8.8) | 0.06 |
absent | 8 (66.7) | 31 (91.2) | |
unknown | 1 (8.3) | 0 (0.0) | |
allogeneic HSCT | |||
performed | 7 (58.3) | 10 (29.4) | 0.09 |
not performed | 5 (41.7) | 24 (70.6) | |
